|
| Monday, 20 November 2017, 14:50 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| Equipped with Functions to Support Looking After Patients |
TOKYO, Nov 20, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 (35th) IT Awards held by the Japan Institute of Information Technology (JiIT).
 | | Front of e-OKUSURI-SAN |
http://www.acnnewswire.com/topimg/Low_FronteOKUSURISAN.jpg
Front of e-OKUSURI-SAN
The IT Awards are given to companies, organizations, other bodies and individuals in recognition of results from notable efforts made in "business innovation through high-level use of IT" by the JiIT, whose designated aim is to promote improvements in productivity in the activities of Japanese industry and government bodies as well as implementation of effective management systems. The "IT Business Award" received by Eisai was awarded based on the verification of notable results in realizing a strategic advantage as well as contributing to management via expansion and creation of business through the effective implementation and use of IT in business activities.
e-OKUSURI-SAN supports treatment administration for patients, families, pharmacists, nurses and caregivers, by ensuring that the prescribed dosage of medicine is administered at the scheduled time, thus helping to prevent patients from forgetting to take medicine or overdosing. The device is also equipped with a function to support looking after patients by allowing those concerned, including family and pharmacists, to remotely confirm a patient's record of medicine administration via an exclusive cloud website system.
In the demonstration experiments conducted ahead of the launch of e-OKUSURI-SAN as well as hearings post-launch, various benefits were observed, including an increase in administration rates, contribution to prevention of overdosing, a reduction in the burden on families, pharmacists, nurses and caregivers to support patients, and an enhancement in interprofessional collaboration through the provision of administration information.
In the selection for this award, the results of the new value provided by e-OKUSURI-SAN to home care patients as well as families and medical and nursing care professionals supporting the rehabilitation activities of patients were assessed, and selected for the "IT Business Award."
Eisai has been engaged for many years in activities for "creating communities where people can live with peace of mind." In carrying out these activities, Eisai has identified real world needs and issues. By providing solutions to these needs and issues in cooperation with stakeholders including local governments, medical institutions and pharmacies, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients and their families.
About e-OKUSURI-SAN
Up to four doses can be scheduled per day (morning, middle of the day, night, before bed), with a week's worth of medicine able to be set in the device. At the scheduled time, a tray with a medicine case slides out, with simultaneous audio and visual prompts. If the case has not been taken from the tray, the snooze function can be used to replay the audio prompts. If 40 minutes have passed without the medicine case being taken from the tray, the medicine case will be automatically retracted into the device. As a general rule, medicine cases cannot be retrieved until the next scheduled administration time to prevent patients from overdosing. Information on medicine administration is encrypted and managed individually on an exclusive website on the cloud. It is possible to have an email sent to registered individuals such as family members or pharmacists whenever a medicine case has been taken or if a medicine case was retracted without being taken.
Monthly data can be viewed as a line graph or table, making it easy to see if a patient is regularly following administration times or not. Eisai Co., Ltd. markets e-OKUSURI-SAN in Japan mainly through pharmacies, medical institutions and care facilities. For inquiries relating to the device, please visit: http://e-okusurisan.com (available in Japanese only)
* e-OKUSURI-SAN is not a medical device.
About the Japan Institute of Information Technology
The Japan Institute of Information Technology (JiIT) was established in 1981 as an "organ for the promotion of management innovation through the utilization of IT." Conducting survey research and development into the digitalization of companies and encouraging the spread and implementation of the results, the JiIT aims to contribute the healthy development of Japanese society, economy and industry. Working to select themes in accordance with the needs of the times and expand its activities, the JiIT is pushing forward with the sound digitalization of both industries and companies.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Nov 20, 2024 10:51 HKT/SGT |
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Nov 20, 2024 09:24 HKT/SGT |
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Nov 15, 2024 16:33 HKT/SGT |
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Nov 15, 2024 13:31 HKT/SGT |
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Nov 5, 2024 10:35 HKT/SGT |
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Nov 1, 2024 12:56 HKT/SGT |
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Oct 31, 2024 12:56 HKT/SGT |
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Oct 31, 2024 10:33 HKT/SGT |
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Oct 17, 2024 19:01 HKT/SGT |
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Oct 17, 2024 14:59 HKT/SGT |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| More news >> |
 |
|
|
|
